Opaleye Management Inc.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Opaleye Management Inc. reported 58 stock positions worth $1.1 billion. Its top holding was Liquidia (LQDA) at 17.7% of the portfolio, followed by Eton Pharmaceuticals (ETON, 9.4%) and Harrow (HROW, 9.2%). Compared with Q1 2026, it opened 13 new positions, sold out of 9, added to 15 and reduced 13. The biggest buy was a new position in Immix Biopharma (IMMX) and the biggest sale Harrow (HROW, shares −15%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001595855
- Portfolio Value
- $1.1B (Q2 2026)
- SEC Filing
- 0001420506-26-001803 ↗ filed Aug 14, 2026
Holdings Value
Holdings 58 stocks · $1.1B
| LQDA Liquidia Corp. | 17.67% | 2,447,500 | $195.1M | Reduce -3.8% |
| ETON Eton Pharmaceuticals Inc. | 9.38% | 2,860,000 | $103.5M | No change |
| HROW Harrow Inc. | 9.23% | 2,400,000 | $101.9M | Reduce -15.3% |
| IRON Disc Medicine Inc. | 5.66% | 855,000 | $62.5M | Add +103.1% |
| URGN Urogen Pharma Ltd. | 4.80% | 1,439,996 | $53.0M | Add +0.7% |
| APGE Apogee Therapeutics Inc. | 4.69% | 390,000 | $51.8M | No change |
| MGTX Meiragtx Holdings PLC | 4.34% | 3,550,000 | $48.0M | Add +67.2% |
| SLGL Sol-Gel Technologies Ltd. | 3.36% | 500,000 | $37.1M | No change |
| RZLT Rezolute Inc. | 2.97% | 6,300,000 | $32.8M | No change |
| TGTX TG Therapeutics Inc. | 2.66% | 535,000 | $29.4M | No change |
| IMMX Immix Biopharma Inc. | 2.19% | 2,345,000 | $24.2M | New |
| CBIO Crescent Biopharma Inc. | 2.15% | 1,319,351 | $23.7M | Add +0.5% |
| STOK Stoke Therapeutics Inc. | 2.07% | 700,000 | $22.9M | No change |
| ACOG Alpha Cognition Inc. | 1.89% | 2,895,467 | $20.9M | Add +13.0% |
| EWTX Edgewise Therapeutics Inc. | 1.84% | 500,000 | $20.3M | No change |
| RVMD Revolution Medicines Inc. | 1.70% | 100,000 | $18.7M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 1.63% | 745,000 | $18.0M | New |
| ALMS Alumis Inc. | 1.40% | 550,000 | $15.5M | No change |
| CDXS Codexis Inc. | 1.39% | 6,785,000 | $15.3M | No change |
| REPL Replimune Group Inc. | 1.39% | 1,384,993 | $15.3M | New |
| XOMA Xoma Royalty Corporation | 1.30% | 338,374 | $14.4M | Add +12.8% |
| MBX MBX Biosciences Inc. | 1.30% | 260,000 | $14.4M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 1.23% | 122,500 | $13.6M | Reduce -0.4% |
| EDIT Editas Medicine Inc. | 1.13% | 3,861,930 | $12.5M | Add +100.4% |
| PTGX Protagonist Therapeutics Inc. | 1.11% | 100,000 | $12.3M | No change |
| CABA Cabaletta Bio Inc. | 1.09% | 3,863,800 | $12.0M | Add +180.0% |
| QTTB Q32 Bio Inc. | 1.07% | 931,000 | $11.9M | Reduce -25.9% |
| ANNX Annexon Inc. | 0.89% | 1,714,451 | $9.8M | Reduce -26.5% |
| VSTM Verastem Inc. | 0.62% | 1,800,000 | $6.9M | New |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.62% | 1,412,656 | $6.9M | No change |
| RLMD Relmada Therapeutics Inc. | 0.59% | 935,000 | $6.5M | No change |
| OCUL Ocular Therapeutix Inc. | 0.53% | 600,000 | $5.9M | No change |
| TRVI Trevi Therapeutics Inc. | 0.52% | 310,000 | $5.8M | Reduce -10.2% |
| BBOT Bridgebio Oncology Therapeut | 0.48% | 700,000 | $5.3M | Add +1213.8% |
| LYEL Lyell Immunopharma Inc. | 0.44% | 344,025 | $4.8M | Add +334.9% |
| IRD Opus Genetics Inc. | 0.42% | 1,125,000 | $4.6M | Add +0.5% |
| FDMT 4D Molecular Therapeutics Inc. | 0.40% | 334,437 | $4.4M | Add +197.8% |
| NTLA Intellia Therapeutics Inc. | 0.38% | 250,000 | $4.2M | Add +2.0% |
| VYGR Voyager Therapeutics Inc. | 0.38% | 1,185,000 | $4.1M | Add +3.0% |
| BDSX Biodesix Inc. | 0.37% | 180,000 | $4.1M | Reduce -24.4% |
| RCKT Rocket Pharmaceuticals Inc. | 0.31% | 1,000,000 | $3.4M | Add +4.7% |
| JBIO Jade Biosciences Inc. | 0.29% | 145,000 | $3.2M | Reduce -66.1% |
| SNWV Sanuwave Health Inc. | 0.28% | 306,140 | $3.1M | Reduce -68.8% |
| FBIO Fortress Biotech Inc. | 0.25% | 890,000 | $2.7M | Reduce -14.6% |
| DERM Journey Medical Corp. | 0.22% | 350,000 | $2.5M | Reduce -63.5% |
| PHAT Phathom Pharmaceuticals Inc. | 0.18% | 185,589 | $2.0M | New |
| INBX Inhibrx Biosciences Inc. | 0.17% | 20,291 | $1.9M | New |
| ENTA Enanta Pharmaceuticals Inc. | 0.17% | 125,000 | $1.8M | No change |
| COAG Hemab Therapeutics Holdings | 0.16% | 47,652 | $1.8M | New |
| TRAX First Tracks Biotherapeutics | 0.12% | 65,000 | $1.3M | New |
| CGON CG Oncology Inc. | 0.11% | 17,789 | $1.3M | Reduce -81.2% |
| BHVN Biohaven Ltd. | 0.10% | 77,915 | $1.2M | New |
| AVIR Atea Pharmaceuticals Inc. | 0.10% | 235,000 | $1.1M | Reduce -27.1% |
| KTTA Pasithea Therapeutics Corp. | 0.10% | 2,050,000 | $1.1M | New |
| ADCT Adc Therapeutics SA | 0.07% | 700,000 | $749K | New |
| OKYO Okyo Pharma Ltd. | 0.05% | 375,204 | $563K | New |
| PTN Palatin Technologies Inc. | 0.02% | 20,500 | $221K | New |
| ADGM Adagio Medical Holdings Inc. | 0.00% | 18,444 | $13K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| HROW Harrow Inc. | Reduce -15.3% | 9.23% | −3.92 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -0.4% | 1.23% | −3.42 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −2.57 |
| SNWV Sanuwave Health Inc. | Reduce -68.8% | 0.28% | −1.96 |
| ANNX Annexon Inc. | Reduce -26.5% | 0.89% | −0.81 |
| CGON CG Oncology Inc. | Reduce -81.2% | 0.11% | −0.73 |
| ASRT Assertio Holdings Inc. | Sold out | 0.00% | −0.67 |
| STRO Sutro Biopharma Inc. | Sold out | 0.00% | −0.63 |
| TECX Tectonic Therapeutic Inc. | Sold out | 0.00% | −0.50 |
| JBIO Jade Biosciences Inc. | Reduce -66.1% | 0.29% | −0.50 |
| DERM Journey Medical Corp. | Reduce -63.5% | 0.22% | −0.37 |
| RIGL Rigel Pharmaceuticals Inc. | Sold out | 0.00% | −0.25 |
| NXTC Nextcure Inc. | Sold out | 0.00% | −0.20 |
| FBIO Fortress Biotech Inc. | Reduce -14.6% | 0.25% | −0.14 |
| AVIR Atea Pharmaceuticals Inc. | Reduce -27.1% | 0.10% | −0.13 |
| PERSPECTIVE THERAPEUTICS INC | Sold out | 0.00% | −0.11 |
| PLX Protalix Biotherapeutics Inc. | Sold out | 0.00% | −0.10 |
| BDSX Biodesix Inc. | Reduce -24.4% | 0.37% | −0.09 |
| LBRX LB Pharmaceuticals Inc. | Sold out | 0.00% | −0.05 |
| TRVI Trevi Therapeutics Inc. | Reduce -10.2% | 0.52% | −0.02 |
| QTTB Q32 Bio Inc. | Reduce -25.9% | 1.07% | +0.01 |
| LQDA Liquidia Corp. | Reduce -3.8% | 17.67% | +5.97 |
Portfolio Buys Q1 2026 → Q2 2026
| IMMX Immix Biopharma Inc. | New | 2.19% | +2.19 |
| IRON Disc Medicine Inc. | Add +103.1% | 5.66% | +2.12 |
| MGTX Meiragtx Holdings PLC | Add +67.2% | 4.34% | +1.92 |
| GLUE Monte Rosa Therapeutics Inc. | New | 1.63% | +1.63 |
| URGN Urogen Pharma Ltd. | Add +0.7% | 4.80% | +1.41 |
| REPL Replimune Group Inc. | New | 1.39% | +1.39 |
| VSTM Verastem Inc. | New | 0.62% | +0.62 |
| CABA Cabaletta Bio Inc. | Add +180.0% | 1.09% | +0.60 |
| EDIT Editas Medicine Inc. | Add +100.4% | 1.13% | +0.51 |
| BBOT Bridgebio Oncology Therapeut | Add +1213.8% | 0.48% | +0.42 |
| FDMT 4D Molecular Therapeutics Inc. | Add +197.8% | 0.40% | +0.27 |
| LYEL Lyell Immunopharma Inc. | Add +334.9% | 0.44% | +0.23 |
| PHAT Phathom Pharmaceuticals Inc. | New | 0.18% | +0.18 |
| INBX Inhibrx Biosciences Inc. | New | 0.17% | +0.17 |
| COAG Hemab Therapeutics Holdings | New | 0.16% | +0.16 |
| IRD Opus Genetics Inc. | Add +0.5% | 0.42% | +0.12 |
| TRAX First Tracks Biotherapeutics | New | 0.12% | +0.12 |
| BHVN Biohaven Ltd. | New | 0.10% | +0.10 |
| KTTA Pasithea Therapeutics Corp. | New | 0.10% | +0.10 |
| ADCT Adc Therapeutics SA | New | 0.07% | +0.07 |
| XOMA Xoma Royalty Corporation | Add +12.8% | 1.30% | +0.06 |
| OKYO Okyo Pharma Ltd. | New | 0.05% | +0.05 |
| ACOG Alpha Cognition Inc. | Add +13.0% | 1.89% | +0.04 |
| PTN Palatin Technologies Inc. | New | 0.02% | +0.02 |
| NTLA Intellia Therapeutics Inc. | Add +2.0% | 0.38% | −0.03 |
| RCKT Rocket Pharmaceuticals Inc. | Add +4.7% | 0.31% | −0.14 |
| VYGR Voyager Therapeutics Inc. | Add +3.0% | 0.38% | −0.21 |
| CBIO Crescent Biopharma Inc. | Add +0.5% | 2.15% | −1.03 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 58 | $1.1B | LQDA, ETON, HROW, IRON, URGN |
| Q1 2026 | 54 | $759.2M | HROW, LQDA, ETON, SLGL, RYTM |
| Q4 2025Amended | 54 | $757.9M | HROW, LQDA, ETON, RYTM, APGE |
| Q3 2025 | 42 | $702.7M | HROW, ETON, LQDA, RYTM, IMNM |
| Q2 2025Amended | 39 | $483.6M | HROW, ETON, IMNM, SNWV, LQDA |
| Q1 2025 | 43 | $438.3M | HROW, ETON, SNWV, LQDA, RYTM |
| Q4 2024 | 37 | $560.7M | HROW, TGTX, CDXS, ETON, OCUL |
| Q3 2024 | 42 | $591.4M | HROW, TGTX, OCUL, ARVN, CDXS |
| Q2 2024 | 49 | $430.0M | HROW, TGTX, OCUL, RYTM, KROS |
| Q1 2024Amended | 51 | $455.6M | OCUL, HROW, TGTX, KROS, RYTM |